Seegene and Springer Nature Launch 2025-2026 Nature Awards MDx Impact Grants for Antibiotic Resistance Research

Seegene and Springer Nature Introduce the 2025-2026 Nature Awards MDx Impact Grants

Seegene Inc., a global leader in molecular diagnostics, has announced the opening of applications for the 2025-2026 Nature Awards MDx Impact Grants in collaboration with Springer Nature, a leading scientific publisher. These grants are aimed at tackling one of the most urgent public health challenges worldwide: antibiotic resistance in urinary tract infections (UTI-DR).

The program marks its third iteration since its launch in 2023, inviting researchers globally to submit proposals for product development and clinical research projects. Applicants may propose research focused on up to 18 specific resistance genes associated with UTIs. Successful candidates will receive funding of up to $600,000, as well as access to Seegene’s syndromic PCR assays, instruments, consumables, and software to aid in the development of innovative diagnostic solutions.

Richard Hughes, Vice President of Publications at Springer Nature, emphasized their commitment to fostering connections among scientists and amplifying innovative research. He stated, "Through this program, we aim to help researchers develop diagnostic solutions that can make a significant impact on global healthcare."

Dr. Jik Young Park, Vice President and Head of R&D Division at Seegene, highlighted the company's role in providing tools and technologies for scientists and researchers to transform innovative ideas into real solutions. He expressed that in collaboration with Springer Nature, they are advancing global research efforts by supporting scientists with funding and access to their syndromic PCR technology. Their ultimate goal is to accelerate the development of molecular diagnostics that align with their vision of creating a 'world free from diseases.'

The Nature Awards MDx Impact Grants are intended to complement ongoing global initiatives in diagnostics and provide researchers with the necessary resources to fast-track practical solutions. The previous cycle, 2024-2025, supported projects focused on rapid detection of ViruResist Klebsiella pneumoniae and multiplex PCR assays for viral detection in immunocompromised patients.

About Seegene

Seegene has established itself as a pioneer in molecular diagnostics with over 20 years in research, development, manufacturing, and commercialization of real-time syndromic PCR technology. During the COVID-19 pandemic, the company provided over 340 million tests across more than 100 countries, reinforcing its global impact.

Seegene’s patented quantitative syndromic PCR technology enables the simultaneous detection of up to 14 pathogens causing similar symptoms in a single tube. Through multiplex panel testing, coverage can be expanded to include dozens of clinically significant pathogens. This innovation not only offers quantitative insights but also provides information on coinfection status—a unique advantage in managing complex infections.

With its Technology Sharing Initiative, Seegene integrates its quantitative PCR technology with the Seegene Digitalized Development System (SGDDS) to co-develop tailored diagnostic products with leading institutions and experts worldwide. By promoting global collaboration, the company continues to work toward its vision of a "world free from diseases."

About Nature Portfolio

Nature Portfolio provides high-quality products and services in biological, physical, chemical, and applied sciences to serve the scientific community. Founded in 1869, Nature has become the leading international weekly science journal. The Nature Portfolio also encompasses research journals, open-access journals, and provides a host of services for researchers, including in-person and online training, as well as expert editing and language services. For more information, visit nature.com and follow on Twitter @Nature.

For further inquiries, please contact: